Beta-blockers helps to reduce risk for knee osteoarthritis,
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A study was carried out to see whether there was a connection between beta-blocker prescription and the first primary-care consultation for knee OA, hip OA, knee pain, and hip pain.

Participants aged more than 40years in receipt of new oral blocker prescriptions were propensity score (PS) matched to an unexposed control. Cox proportional hazard ratios (HRs) and 95% confidence intervals (CI) were calculated, and adjusted for non-osteoporotic fractures, number of primary-care consultations for knee or hip injury, and, the number of primary-care consultations, out-patient referrals and hospitalizations in the 12-months preceding cohort entry. Analysis was stratified according to beta-blocker class and for commonly prescribed drugs.

Results:
--111718 beta-blocker exposed participants were 1:1 PS matched to unexposed controls.

--beta-blocker prescription was associated with reduced cumulative risk of knee OA, knee pain, and hip pain consultations with aHR 0.90; 0.88, and 0.85, respectively.

--Propranolol and atenolol were associated with a lower incidence of knee OA and knee pain consultations with aHRs between 0.78–0.91.

--beta-blockers were associated with reduced incidence of consultation for large-joint lower-limb OA/pain as a composite outcome, defined as earliest of knee OA, knee pain, hip OA or hip pain consultation (aHR 0.87).

Conclusively, Commonly used beta-blockers have analgesic properties for musculoskeletal pain. Atenolol might be a therapeutic option for OA and cardiovascular co-morbidities in which beta-blockers are indicated, while propranolol may be suitable for people with co-morbid anxiety. A confirmatory randomised controlled trial is needed before clinical practice is changed.

Source: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keab234/6169013
Like
Comment
Share